Roche acknowledges the obvious, extends Spark buyout deadline

The Securities and Exchange Commission filings that Spark released Monday confirm what became apparent when the FTC announced it was subjecting the Roche buyout...

Safety setback for Pfizer, Lilly pain drug should have Regeneron and Teva feeling nervous

The U.S. opioid crisis breathed new life into clinical development of the nerve-growth factor (NGF) inhibitors tanezumab and fasinumab. The drug class had been nearly...

FDA’s Woodcock defends accelerated approvals and talks of culture shift in clinical trials

Over more than three decades at the Food and Drug Administration, Janet Woodcock has seen the biotech industry mature from the early days of biologics...

Gilead firms up path to market for key arthritis drug

A filing this year for filgotinib could set up a potential market launch in 2020, which would be one to two years earlier than...
Wave Life Sciences has joined the biopharma sector's gold rush to treat DMD, a genetic disorder that causes progressive musculoskeletal disability in boys. So far,...
Despite spending billions on R&D, big pharma doesn't punch its weight in discovering the new molecules that eventually make it to market. Instead, it's...
Aimed at the molecular catalysts of tumor growth, targeted therapies are treatment mainstays across a wide range of cancer types. 

Follow RXMonthly

News

BioMarin confirms timeline for hemophilia gene therapy, putting pressure...

Hemophilia has become one of the most competitive battlegrounds in the emerging field of gene therapy. While BioMarin remains the frontrunner to market, a...

BioNTech buys MAB Discovery’s antibody research unit

Known for its work in the field of messenger RNA therapeutics, BioNTech is looking for new ways to grow. Earlier this month, the private...

Intra-Cellular’s depression drug goes 1 for 2 in Phase...

Intra-Cellular's success and failure demonstrate the difficulty of developing psychiatric drugs. Unqualified clinical success in depression is particularly challenging, as high placebo responses can...

Biotechs dive deeper into targeted cancer research, despite costs

"It could become very challenging for a small biotech company, or even a pharma company, to cover that part of a clinical trial test,"...

Latest articles

CMS chief declines to provide details on Trump healthcare plan

The administration faces increasing pressure to release a concrete healthcare plan as Democratic presidential candidates are eager to keep the national conversation focused...

Roche cancer drug the 3rd approved for pan-tumor use

Aimed at the molecular catalysts of tumor growth, targeted therapies are treatment mainstays across a wide range of cancer types. 

Novo faces shareholder suit over insulin sales disclosures

Novo is best known for its insulin products like Levemir (insulin detemir) and Tresiba (insulin degludec), as well as other diabetes treatments like...

Celgene wins approval for drug key to Bristol buyout

Approval of Inrebic, which was previously known as fedratinib, is the first domino to fall in Bristol-Myers bet on Celgene's product pipeline. 

Subscribe to our newsletter